Royalty Report: Drugs, Biotechnology, cardiac – Collection: 28172

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Biotechnology
  • cardiac
  • Disease
  • Therapeutic
  • Stem cells
  • Medical
  • Pharmaceuticals
  • Cancer
  • Enzymes
  • Regenerative medicine
  • Specialty
  • Diagnostic
  • Test/Monitoring
  • Supply
  • Molecular
  • Proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28172

License Grant
The Licensor, a nonprofit American academic medical center, grants to the Belgium Licensee an exclusive license to make, have made, use, modify, enhance, promote, market and/or sell the Licensed Invention whether or not patented, and a non-exclusive right to use the Licensed Know-How, in the Territory within the Field of Heart Disease.
The Licensee may assigning or subcontract the rights with permission from the Licensor.
License Property
Licensed inventions means Cardiogenic Cocktail for the production of Cardiac Cells and Stem Cell Based Therapy for Non-ischemic Cardiomyopathic Heart Failure.

2004-182 Derivation of a Cardiopoetic Cellular Phenotype from a Stem Cell Source.

And the related Patents and Patent Applications;

06/592,871 Stem Cells and treatment of Vascular Tissue

06/680,775 Treating Cardiovascular Tissue

06/832,845 Methods and Materials for providing Cardiac Cells

PCT/US2005/026800 Treating Cardiovascular Tissue

PCT/US2008/064895 Methods and Materials for using Cells to treat Heart Tissue

PCT/US2009/044714 Compositions and Methods for Using Cells to treat Heart Tissue

PCT/US2009/044751 Methods for determining the Cardio Generative Potential of Mammalian Cells

3. Paragraph 2.02 is replaced with the following;

Field of Use
FIELD OF USE means cardiovascular regeneration or protection.

Field of Use means treatment of embryonic and autologus mesenchymal stem cells to guide development into cardiomyocytes for the treatment of myocardial infarction, ischemic heart disease, ischemic and non-ischemic cardiomyopathy.

The Belgian biopharma company is involved in the discovery, development and commercialisation of regenerative and protective therapies for the treatment of cardiac diseases.

IPSCIO Record ID: 3533

License Grant
The Licensor and the Licensee entered into an Assignment and License Agreement, pursuant to which the Licensor granted the Licensee an exclusive, worldwide license and the assignment of patents relating to certain gene therapy applications of mSCF for the treatment of cardiac ischemia. The Licensee has the right to grant sublicenses to third parties under the agreement.
License Property
Licensor owns certain intellectual property (including an issued United States patent) relating to certain gene therapy methods for delivering stem cell factor coding sequences, in order to treat certain ischemic diseases.

The patents relate to certain gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia.

The Licensor intellectual property and research involves gene therapy technologies.

Field of Use
The Licensee will use the rights to gene therapy applications for the membrane bound form of Stem Cell Factor, or mSCF, for treatment of cardiac ischemia.  Cardiac ischemia occurs when blood flow to your heart muscle is decreased by a partial or complete blockage of your heart's arteries. The decrease in blood flow reduces your heart's oxygen supply and can damage your heart muscle, reducing its ability to pump efficiently.

IPSCIO Record ID: 7393

License Grant
The Licensor has entered into a License Agreement with the Licensee, of Moscow Russia, giving that firm License rights to ERCs (Endometrial Regenerative Cells) for CHF (Congestive Heart Failure) indications in the territory of Russia.
Licensor acknowledges that he has the exclusive right to use the know-how, the exclusive right to permit other persons to use it, and the exclusive right to prevent any unauthorised disclosure and (or) other use of this know-how, and is entitled to dispose of its at his discretion in compliance with the above specified rights.
License Property
In January 2012, the Licensor announced the initiation of the RECOVER-ERC (Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde Coronary Sinus Venous Delivery of Cell Therapy) Phase II clinical trial.

Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function.

Field of Use
The Licensee is providing sponsorship and funding for ongoing Phase II clinical trial in CHF being conducted at the Bakulev Scientific Center for Cardiovascular Surgery.

IPSCIO Record ID: 230517

License Grant
The Licensor granted the Kuwait Licensee the exclusive right to the intellectual property for the licensed use and development in Kuwait and other GCC/Middle East countries.
License Property
The Intellectual Property relates to methods of repairing damaged heart tissue by transplanting myoblasts that express SDF-1 and other therapeutic proteins capable of recruiting other stem cells within a patient’s own body to the cell transplant area.

The IP includes products and technologies like MyoCell for the treatment of heart damage. These are autologous muscle-derived cellular therapies designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

MyoCell is an innovative clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients.

Field of Use
The intent is to offer regenerative treatment options to patients, based on Licensor products and technologies like MyoCell and MyoCell SDF-1.

IPSCIO Record ID: 28064

License Grant
University granted the Licensee an exclusive United States and worldwide license under the patent rights for cardiac disorders.
License Property
Patent shall mean U.S. patent application Serial No.  09/186,755  and PCT application PCT/US98/23878, each filed on 11/5/98; EPO application filed 08/0212000; all assigned to the University entitled Methods for Treatment of Disorders of Cardiac Contractility. Invention entitled Xanthine Oxidase Inhibitors as Calcium-Sensitizing Therapeutic Agents for Heart Failure.
Field of Use
The Licensed Field shall mean therapeutic, diagnostic and commercial use of xanthine oxidase inhibitors for cardiovascular and neuromuscular disease.

IPSCIO Record ID: 7349

License Grant
The Licensee entered into a royalty Agreement with the Licensor and received the following assets from the Licensor
License Property
Certain patents and patent applications and all related active prosecution cases, trade secrets, know-how and certain other intellectual property rights, and all of the Licensor's goodwill with respect to the technology directly related to the research, development and commercialization of certain products and know-how related to hES cells;

Certain biological materials and reagents (including master and working cell banks, original and seed banks, and research, pilot and GMP grade lots and finished product);

Certain regulatory filings for clinical trials for GRNOPC-I for spinal cord injury, including the investigational new drug applications filed with the United States Food and Drug Administration for Licensor’s Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury (Protocol No. CP35A007), and long term follow up of subjects who received GRNOPC1 (Protocol No. CP35A008), and the clinical trial for VAC1 for acute myelogenous leukemia, including a Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML) in complete remission (Protocol No. CP06-151).

US Patent 6,800,480 – Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
US Patent 7,413,902 – Feeder-Free Culture Method for Embryonic Stem Cells
US Patent 6,440,735 – Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
US Patent 7,402,307 – Method for Identifying and Killing Cancer Cells
US Patent 7,824,849 – Cellular Telomerase Vaccine and Its Use for Treating Cancer
US Patent 7,560,281 – Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells
US Patent 8,252,586 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent 8,153,428 – Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells
US Patent 6,667,176 – cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells
US Patent 7,041,438 – Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing
US Patent 7,413,904 – Embryonic Stem Cells Having Genetic Modifications
US Patent 7,410,798 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 7,297,539 – Medium for Growing Human Embryonic Stem Cells
US Patent 7,455,983 – Medium for Growing Human Embryonic Stem Cells
US Patent 8,097,458 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 6,642,048 – Conditioned Media for Propagating Human Pluripotent Stem Cells
US Patent 6,458,589 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 6,506,574 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 7,256,042 – Process for Making Hepatocytes from Pluripotent Stem Cells
US Patent 7,282,366 – Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells
US Patent 7,473,555 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent 8,148,151 – Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
US Patent 6,833,269 – Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells
US Patent 8,148,148 – Neural Progenitor Cell Populations
US Patent 8,252,585 – Neural Progenitor Cell Populations
US Patent 7,250,294 – Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells
US Patent 7,763,463 – Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells
US Patent 6,576,464 – Differentiated Cells Suitable For Human Therapy
US Patent 6,921,665 – Selective Antibody Targeting of Undifferentiated Stem Cells
US Patent 7,732,199 – Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,763,464 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent 7,452,718 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,897,389 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,851,167 – Differentiation Protocol for Making Human Cardiomyocytes

US Patent Application 13/561,296 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent Application 12/170,219 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 12/710,078 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 13/323,567 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 11/917,993 – Suspension Culture of Human Embryonic Stem Cells
US Patent Application 12/277,136 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent Application 13/558,078 – Neural Progenitor Cell Populations
US Patent Application 11/359,341 – Differentiated Cells Suitable For Human Therapy
US Patent Application 11/471,916 – Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

Field of Use
The Licensee is a biotechnology company focused on the emerging field of regenerative medicine, with core technologies centered on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency.

IPSCIO Record ID: 168

License Grant
Licensor hereby grants a royalty-bearing, worldwide, exclusive license, with the right to sublicense, to use the Patent Rights and Know-How to (a) research, develop, make, have made, use, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported Licensed Products, (b) research, develop, use, practice, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported Licensed Processes, and (c) develop, use, perform, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported Licensed Services.

Company granted an exclusive license to use its “ACTCellerate” embryonic stem cell technology and a bank of over 140 diverse progenitor cell lines derived using that technology.

License Property
ACTCellerateâ„¢ is a recently discovered technology that allows the rapid isolation of novel highly purified embryonic progenitor cells. Embryonic progenitors are cells intermediate between embryonic stem cells and fully differentiated cells.  The progenitor cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of embryonic stem cells. Using the ACTCellerate platform technology over 140 distinguishable novel progenitor cell lines have already been created, scaled-up, and banked. These unique cell lines may possess the ability to become a wide array of products never before available to the medical community, with potential applications in research, drug discovery, and human regenerative stem cell therapy.  

The licensed rights include pending patent applications, knowledge and the existing bank of cell lines. The licence is exclusive and worldwide for all commercial purposes, including the development of research products, and therapeutic and diagnostic products for human and veterinary use.  Licensor has an option to reacquire rights to use the technology for the development of certain types of SCs for human therapeutic use in fields re-lated to its core business.

The technology allows the rapid isolation of novel, highly-purified embryonic progenitor cells. The progenitor cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of ESCs. These unique cell lines may have potential applications in research, drug discovery and human regenerative SC therapy.

Patent Rights
103080-069-WO1 (PCT/US06/13519, filed on 4-11-06) Novel uses of cells with Prenatal Patterns of prenatal gene expression, published as WO2007/058671
103080-071-P61 (USSN 60/791,400, filed on Apr. 11, 2006) Methods to accelerate the isolation of novel cell strains from pluripotent ST
103080-071-P66 (USSN 60/850,294, filed on Oct. 6, 2006), Methods to accelerate the isolation ov novel cell strains from pluripotent stem cells
103080-071-P01 (USSN 11/604,047, filed on Nov. 21, 2006), Methods to accelerate the isolation  of novel cell strains from pluripotent STE…
PCT is 103080-071-WO2 (PCT/US2006/45352, filed on Nov. 21, 2006), published as WO 2007/062198.

IPSCIO Record ID: 273380

License Grant
The University, with permissions as applicable, grant an exclusive, sublicensable license for the field of Use in the Territory to
—  practice under the Patent Rights
—  make, have made, use, lease, import, export and/or sell Licensed Products,
—  sell, use and/or practice Licensed Services.

The University grants a non-exclusive license to use Know-how for the Field of Use in the territory to
—  make, have made, use, lease and/or sell Licensed Products
—  sell, use and/or practice Licensed Services.

License Property
The University has rights to patents titles Reactive Oxygen Generating Enzyme and Inhibitor with Nitric Oxide Bioactivity and Uses Thereof, and, Composition for the Treatment and Prevention of Heart Disease and Methods of Using the Same.

The Phase II candidate and all other drugs in the portfolio are designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. All have a dual mechanism of action of inhibiting the creation of reactive oxygen radicals and concurrently providing nitric oxide in the failing heart. The therapeutic target is the ryanodine receptor, the ion channel in the heart that provides the calcium necessary for the heart to beat. The investigational drugs are believed to improve calcium cycling in the heart by acting on the ryanodine receptor to significantly improve the efficiency of heart contractility.

Field of Use
The field of use means all therapeutic uses for allopurinol, oxypurinol, ptcein-6-aldehyde and mixtures thereof, that are provided with a nitrate group thereon, as well as therapeutic uses for any combinations of these agents with nitrates or other NO donors.

The drug portfolio is to develop and commercialize certain of Licensee's proprietary cardiovascular drugs to treat heart failure.

IPSCIO Record ID: 28541

License Grant
University grants Licensee an Exclusive license under the Licensed Patent in the Licensed Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Licensed Territory. Licensee may grant sublicenses in the Licensed Field of Use only during the Exclusive term and only if Licensee is developing or selling Licensed Products, Required Sublicensing.
License Property
University has an assignment of an invention a target and associated compounds useful for regenerative medicine. It is entitled Notch-Mediated Tissue and Organ Repair through Control of Endogenous Stem and Progenitor Cell Behavior.

Licensed Patent means U.S. Patent Application, Serial Number 11/078,899.  

Stem cells have a capacity both for self-renewal and the generation of differentiated cell types. This pluripotentiality makes stem cells unique. In addition to studying the important normal function of stem cells in the regeneration of tissues, researchers have further sought to exploit the potential of in situ and/or exogenous stem cells for the treatment of a variety of disorders. While early, embryonic stem cells have generated considerable interest, the stem cells resident in adult tissues may also provide an important source of regenerative capacity.

11/078,899 (7,837,993) The regenerative potential of aged stem cells is enhanced by activation of the Notch signaling pathway and/or inhibition of TGF-ß signaling pathway. Stem cells in aged tissues are capable of proliferation and tissue regeneration, but in their native setting are not provided with the appropriate signals to do so. By administering tissue regenerating agents, organ stem/progenitor cells are provided with the appropriate signals to regenerate the corresponding differentiated tissues.

Field of Use
Licensed Field of Use means therapeutic uses and associated internal research and drug screening activities.

IPSCIO Record ID: 240469

License Grant
This amendments revises the intellectual property, royalties and identifies potential options to be exercised.  This agreement is for enoximone property and processes.
License Property
Enoximone is a small organic molecule that exhibits highly selective inhibition of type-III phosphodiesterase, or PDE-III, an enzyme that is present in the heart and plays an important regulatory role in cardiac function.

The licensed property is Angiotensin-converting enzyme genetic variant screens; Transgenic model and treatment for heart disease; Transgenic Model for Heart Failure; Method for identifying adrenergic receptor antagonists having good tolerability; Diagnosis and treatment of myocardial failure; Method of treating heart failure; Inhibition of HDAC as a treatment for cardiac hypertrophy; and, Quantitative analysis of closely related protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry.

Field of Use
Licensee is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders.

IPSCIO Record ID: 26263

License Grant
Licensor hereby grants to Licensee, a royalty bearing, exclusive, worldwide License in the Field of  research, development, manufacture and selling of human cells for cell therapy in the treatment of human diabetes and liver diseases.
License Property
The Technology is to research, develop, make, have made, use, sell, offer for sale, import and export Licensed Products, Processes and Services to produce human embryonic stem cells and to produce from those mammalian embryonic cells, differentiated cells for human cell therapy within the Field, and to produce pluripotent cells including ES cells, differentiated human cells for cell therapy within the field.

5,453,366 Method of Cloning Bovine Embryos

6,011,197 Method of Cloning Bovines Using Reprogrammed Non-mbryonic Bovine Cells

6,258,998 Method of Cloning Porcine Animals

5,843,754 Parthenogenic Bovine Oocyte Activation

5,496,720 Parthenogenic Oocyte Activation

09/573,044 Use of embryonic stem cells as nuclear donors during nuclear transfer and use of said techniques to produce chimeric and transgenic animals.

6,194,202 Parthenogenic Oocyte Activation

6,077,710  Parthenogenic Oocyte Activation

6,107,543  Culture of Totipotent Embryonic Inner Cells Mass Cells and Production of Bovine
Animals

Field of Use
The Field shall exclude applications involving the use of cells in the treatment of tumors where the primary use of the cells is the destruction or reduction of tumors and does not involve regeneration of tissue or organ function.

IPSCIO Record ID: 263

License Grant
The Hospital hereby grants the Licensee an exclusive, royalty-bearing license under its Patent Rights in the License Field and the License Territory.
License Property
Pathfinder Cells shall mean a mixed population of mammalian cells, with a mixed CD90 positive phenotype and CD34 negative phenotype, isolated using the methodology described in the patent WO/2006/120476, and which are capable of facilitating, or initiating the repair of mammalian tissue following, by way of example only, insult with an exogenous agent, or degenerative disease, or through the biological ageing processes.

Patent rights shall mean the U.S. Patent Application Number 11/438,790, filed on May 22, 2006 or the equivalent of such application as well as issued patent applications including U.S. Patent Application Number 11/410, 412, 10/984, 645, and 11/132, 687.

Field of Use
Pathfinder Cells are a newly identified mammalian cell type  that have the ability to stimulate tissue regeneration in a number of different organs. PCs are not stem cells and are distinguishable from cell types being developed by other companies for use in regenerative medicine through cell surface and other markers.

IPSCIO Record ID: 7550

License Grant
The Licensee obtained a non-exclusive License to distribute human embryonic stem cell lines made by the Licensor through stem cell banks.
License Property
The term “stem cells” describe all of the cells that can give rise to the different cells found in tissues.  Cells from the same pluripotent stem cells can be used in any patient. This type of cell therapy is referred to as “allogeneic”. This permits the use of a single master stem cell bank in the manufacturing of the therapeutic doses to be used such that one uniform source of starting cells can be readily controlled for consistency, lack of infectious agents and cleared by regulatory agencies.

IPSCIO Record ID: 47933

License Grant
The Spanish University patent families referred to as PCX006 and PCX007 are the subject of a co ownership agreement with the Spanish Licensee. Under the terms of this agreement, the University assigned all exploitation rights, including the right to license or sub-license to third parties.
License Property
University signed an agreement for the Assignment of the Rights to Exploit Spanish invention patents no. 200402355, entitled “IDENTIFICATION AND ISOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE”, and no. 200402083, entitled “Biomaterial for suture”

PCX006 is a patent family claiming a non osteochondral derived multipotent adult stem cell population characterized by a set of biological markers.
PCX007 is a patent family claiming an adipose derived stem cell composition characterized by a panel of cell surface markers, methods of preparation of such a composition and adipose tissue derived stromal stem cells in treating fistula and wounds.

(WO2006037649/11/167,061) IDENTIFICATION AND INSOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE
The present invention relates to isolated multipotent adult cells which are isolated from non-osteochondral mesenchymal tissue and are characterized by the presence and absence of a set of cell surface markers. The invention also relates to a method for identifying and isolating a population of said cells, as well as to the applications thereof, for example, in the manufacture of a pharmaceutical composition for the repair and regeneration of tissues.

Field of Use
The Licensee is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from our proprietary technology platforms of allogeneic, or donor-derived, stem cells.

IPSCIO Record ID: 26667

License Grant
We acquired the Exclusive worldwide rights to US Patent # 6129911, for Liver Stem Cells from Licensor, a non-profit  hospital.  The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.  This patent contains twenty-four claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company's adult stem cell portfolio.
License Property
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.  This patent contains twenty-four claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company's adult stem cell portfolio.  (The Company has an exclusive, long-term license agreement for use of the following patents owned by the hospital related to liver cell lines and Liver Assist Devices (LADs)  US Patent #6,017,760, Isolation and Culture of Porcine Hepatocytes, expires October 9, 2015;  US Patent #6,107,043, Immortalized Hepatocytes, expires February 8, 2019;  US Patent #5,043,260, Perfusion Device for Hepatocytes, expires August 27, 2008;  US Patent #4,795,459, Implantable Prosthetic Device (Endothelial), expires January 3, 2006;  US Patent #6,129,911, Liver Stem Cell, expires October 10, 2017;  US Patent #6,858,146, Artificial Liver Apparatus and Method (Sybiol), expires on February 20, 2019; and  US Patent #6,872,389, Liver Stem Cell, expires on July 8, 2019.)

IPSCIO Record ID: 289172

License Grant
The Canadian Licensor, a non-profit academic health research institute, grants to the Canadian Licensee the exclusive, world-wide, right and license, with the right to sublieense, to use Licensors rights in and to the Licensed Technology and the Licensed Patents in the Field of Use to develop Licensed Products and to make, have made, import, use, offer for sale and sell Licensed Products.
License Property
License relates to certain patents relating to the use of Wnt7a proteins.

Licensor owns technologies relating to protein and small molecule therapies for the treatment of diseases.

1. A Pax-Encoding Vector And Use Thereof US (CIP) 7,384,784

2. Methods And Compositions For Modulating Stem Cell Growth And Differentiation US 7,541,183

3. Novel Stem Cells, Nucleotide Sequences And Proteins Therefrom US 12/094,585

4. Use Of Cardiotropbln To Modulate Stem Cell Proliferation US 11/318,413

5. Pancreatic Regeneration PCT/CA2009/001220

6. Treatment of Muscle Disease Characterized by Insulin Resistance US Provisional 61/179,040

7. Composition and Methods for Modulating Stem Cells US Provisional 61/172,832

8. Cardiac Stem Cell Proliferation Proteins, Fragments Thereof And Methods Of Modulating Stem Cell Proliferation And Differentiation US 12/156,953

9. Prodrugs of Biguanlde Derlvatlves For The Treatment of Muscular Disorders US Provisional 61/244,669

Field of Use
Licensee has identified Wnt7a as a natural promoter of SSCs to drive muscle regeneration and are initially focused on developing Wnt7a protein analogs for the treatment of muscular dystrophies. Licensee believes that our regenerative approach for treating muscular dystrophies holds significant therapeutic promise and is distinct from other approaches, which focus on preventing muscle degeneration.

Field of Use means all fields.

IPSCIO Record ID: 240578

License Grant
The University grants a worldwide, exclusive license under Licensed Subject matter to discover, research, develop, make, have made, use offer for sale, sell and import Licensed Products and Identified Products for use within Licensed Field.
License Property
Licensed Product means any compound, assay, method, reagent, technology, product or service comprising Licensed Subject Matter.

Licensed Subject Matter means inventions, discoveries, assays and processes covered by Patent Rights and/or Technology Rights within Licensed Field.

The patents are for Methods and Compositions Relating to Muscle Selective Calcineurin Interacting Protein (MCIP).

Field of Use
Licensed field means treatment, prevention, diagnosis and/or prognosis of cardiac hypertrophy, heart disease and heart failure; and determination of predisposition to cardiac hypertrophy, heart disease and heart failure.

IPSCIO Record ID: 28403

License Grant
Licensor hereby grants to Licensee, and Licensee hereby accepts, subject to the terms and conditions hereof, a royalty bearing, exclusive license in the Territory in the Field and under the Licensed Technology to (a) research, develop, make, have made, use, sell, offer for sale, import and export Licensed Products, (b) research, develop, use, practice, sell, offer for sale, import and export Licensed Processes and (c) develop, use, perform, sell, offer for sale, import and export Licensed Services. By way of example, but not in limitation, Licensee shall have the right to use Licensed Technology within the Field to produce mammalian embryonic stem (ES) cells and to produce from those mammalian embryonic cells, differentiated cells for human therapeutic purposes or for commercial research purposes, including drug screening assays, and to produce pluripotent cells including ES cells, differentiated human cells for human diagnostic and therapeutic purposes and/or for commercial research purposes, including drug screening assays.
License Property
60/382,616 Nuclear Transfer-Generated Stem Cells for Transplantation Having Homozygous MHC Alleles, and Methods for Making and Using Such a Stem Cell Bank

09/736,268 Transfer to De-Differentiate Recipient Cells

Field of Use
Field shall mean (1) the research, development, manufacture and selling of human and non-human animal cells for commercial research use, including small molecule and other drug testing and basic research and (2) the manufacture and selling of human cells for therapeutic and diagnostic use in the treatment of human (a) diabetes and (b) liver diseases; but Field shall exclude applications involving the use of cells in the treatment of tumors where the primary use of the cells is the destruction or reduction of tumors and does not involve regeneration of tissue or organ function.

IPSCIO Record ID: 7466

License Grant
The Licensor, government public health organization, hereby grants and Licensee accepts, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
Development and commercialization of this technology will provide treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion and inflammation of the cardiovascular system. Development and commercialization of this technology will also provide treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.
Field of Use
Fields of Use of the Licensed Property is for prevention, treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion, inflammation of the cardiovascular system and the treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.

IPSCIO Record ID: 213335

License Grant
Seller desires to sell, transfer and assign to Buyer certain assets related to the vepoloxamer product candidate including all tangible and intangible property related to polyoxyethylene containing surface-active agents owned or controlled by Seller as of the Effective Date. Vepoloxamer is used for the treatment of vaso-occlusive crisis in patients with sickle cell disease and in development for the treatment of patients with heart failure.  US Patents 9757411;  9,403,941 are included in the assets.
License Property
Seller holds certain rights to a discontinued vepoloxamer product candidates use in cardiac disease. Storage Product means a for use in the ex vivo storage of cells intended for future transplant or transfusion into patients. Therapeutic Product is for direct administration to a patient for the treatment of a medical condition.
Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.